Sign in →

Test Code GNMY9 MYH9-Related Disorders, MYH9 Gene, Next-Generation Sequencing, Varies


Ordering Guidance


This test is designed to evaluate MYH9-related disorders, including May-Hegglin disorder/anomaly and Sebastian syndrome, and to be utilized for genetic confirmation of a phenotypic diagnosis of an MYH9-related disorder.

 

If testing for hereditary platelet disorders using a larger panel is desired, a 70-gene platelet disorder panel is available; order GNPLT / Platelet Disorders, Comprehensive Gene Panel, Next-Generation Sequencing, Varies.

 

This test is not designed to evaluate for hereditary bleeding disorders. For patients with clinical suspicion of an inherited bleeding disorder, it is important to exclude plasmatic factor deficiencies (eg, von Willebrand disease, hemophilia, or other factor deficiencies) prior to considering an inherited platelet function defect. If bleeding is the indication for testing and testing for hereditary bleeding disorders is desired, bleeding panels are available. For more information see GNBLF / Bleeding Disorders, Focused Gene Panel, Next-Generation Sequencing, Varies or GNBLC / Bleeding Disorders, Comprehensive Gene Panel, Next-Generation Sequencing, Varies.

 

For assessment of hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome, order PTEM / Platelet Transmission Electron Microscopic Study, Whole Blood.

 

For assessment of hereditary platelet disorders due to quantitative surface glycoprotein deficiencies, order PLAFL / Platelet Glycoprotein Flow Platelet Surface Glycoprotein by Flow Cytometry, Blood.

 

Testing for the MYH9 gene as part of a customized panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known variants testing) is available for the MYH9 gene. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Necessary Information


Platelet Esoteric Testing Patient Information is required. Testing may proceed without the patient information, however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.



Specimen Required


Specimen Type: Whole blood

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated


Forms

1. Platelet Esoteric Testing Patient Information is required.

2. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

3. If not ordering electronically, complete, print, and send an Coagulation Test Request (T753) with the specimen.

Useful For

Evaluating MYH9-related disorders, including May-Hegglin disorder/anomaly and Sebastian syndrome, in patients with a personal or family history suggestive of an MYH9-related disorder

 

Diagnosing MYH9-related disorders, including May-Hegglin disorder/anomaly and Sebastian syndrome, for patients in whom phenotypic testing is nondiagnostic, but there is a strong clinical suspicion of the MYH9-related disorder

 

Confirming an MYH9-related disorder diagnosis with the identification of a known or suspected disease-causing alteration in the MYH9 gene

 

Determining the disease-causing alterations within the MYH9 gene to delineate the underlying molecular defect in a patient with a laboratory diagnosis of an MYH9-related disorder

 

Identifying the causative alteration for genetic counseling purposes

 

Prognosis and risk assessment based on the genotype-phenotype correlations

 

Providing a prognosis in syndromic MYH9-related disorders

 

Carrier testing for close family members of an individual with an MYH9-related disorder diagnosis

 

This test is not intended for prenatal diagnosis

Testing Algorithm

The clinical workup for detecting inherited platelet disorders should begin with a careful review of a patient’s complete blood cell count and platelet indices results, peripheral blood smear, and other platelet tests, such as light transmission platelet aggregometry, electrical impedance whole blood aggregometry, and platelet function analyzer 100 (PFA-100). Platelet transmission electron microscopy is an essential tool for laboratory diagnosis of various hereditary platelet disorders, and platelet flow cytometric analysis is the preferred method to assess hereditary platelet disorders due to quantitative surface glycoprotein deficiencies

 

Due to the reduced sensitivity of functional testing, occasionally, the clinical picture may be consistent with a defect in primary hemostasis, but results of platelet tests may be normal or non-diagnostic.

 

Genetic testing for hereditary platelet disorders is indicated if:

-Platelet tests indicate a deficiency or functional abnormality, and abnormal platelet or white blood cell morphology by light or electron microscopy

-There is a clinical suspicion for a hereditary platelet disorder due to family history or patient’s clinical presentation

-Acquired causes of deficiencies associated with platelet disorders have been excluded

 

If a platelet disorder is a concern, a set of clinical guidelines from the British Society for Haematology on testing for heritable platelet disorders is freely available.(1)

Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

Reporting Name

MYH9 Gene, Full Gene NGS

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(8) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Day(s) Performed

Varies

Report Available

28 to 42 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81479

LOINC Code Information

Test ID Test Order Name Order LOINC Value
GNMY9 MYH9 Gene, Full Gene NGS 105332-1

 

Result ID Test Result Name Result LOINC Value
619300 Test Description 62364-5
619301 Specimen 31208-2
619302 Source 31208-2
619303 Result Summary 50397-9
619304 Result 82939-0
619305 Interpretation 69047-9
619306 Additional Results 82939-0
619307 Resources 99622-3
619308 Additional Information 48767-8
619309 Method 85069-3
619310 Genes Analyzed 82939-0
619311 Disclaimer 62364-5
619312 Released By 18771-6